COPAXONE^® FOR MULTIPLE SCLEROSIS TREATMENT

Start therapy off right with our supportive resources and tools.

Have a discussion with your patients about what to expect when they’re being treated with COPAXONE^® (glatiramer acetate injection), what their financial options are, and how they can inject safely. Then point them to these downloadable guides, confident they’re well-informed with answers to their questions at their fingertips.

Downloadable Guides

Healthy Skin Practices

Guidance on maintaining healthy skin and managing common injection site reactions throughout COPAXONE^® therapy.

DOWNLOAD GUIDE COPAXONE® Healthy Skin Guide.

Injection Guide

Includes a printable preparation mat, supplies checklist, and guidance stressing regular injection site rotation.

DOWNLOAD GUIDE COPAXONE® Injection Guide.

Travel Planning Guide

Tips for organizing travel, proper storage of COPAXONE®, and staying on therapy while away from home.

DOWNLOAD GUIDE COPAXONE® Travel Planning Guide.

Benefits Discussion Guide

Start your patients off right by assessing their prescription drug coverage with a few simple questions.

DOWNLOAD GUIDE Benefits Guide.

Additional patient resources available on COPAXONE.com.

Share these links with your patients if they ask for more information on multiple sclerosis (MS):

Read frequently asked questions about COPAXONE^®

How does COPAXONE^® work in the body?

COPAXONE^® is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.¹ This hypothesis is supported by studies utilizing experimental autoimmune encephalomyelitis (EAE), a condition induced in animals through immunization against CNS-derived material containing myelin.¹ Studies in animals and in vitro systems suggest that upon administration, glatiramer acetate–specific suppressor T cells are induced and activated in the periphery.¹

How often is COPAXONE^® administered?

COPAXONE^® 40 mg is used 3 times a week, with injections at least 48 hours apart around the same time on the same 3 days each week. It can be administered manually or with the autoject^®2 for glass syringe.

Indication

COPAXONE^® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Contraindication: COPAXONE^® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Immediate Post-Injection Reaction: Approximately 16% of patients exposed to COPAXONE^® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of patients exposed to COPAXONE^® 40 mg per mL compared to none on placebo experienced a constellation of symptoms that may occur immediately (within seconds to minutes, with the majority of symptoms observed within 1 hour) after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Chest Pain: Transient chest pain was noted in 13% of COPAXONE^® 20 mg per mL patients compared to 6% of placebo patients, and approximately 2% of COPAXONE^® 40 mg per mL patients compared to 1% on placebo. While some episodes of chest pain occurred in the context of the Immediate Post-Injection Reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

Lipoatrophy and Skin Necrosis: At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Potential Effects on Immune Response: Because COPAXONE^® can modify immune response, it may interfere with immune functions. For example, treatment with COPAXONE^® may interfere with recognition of foreign antigens in a way that would undermine the body’s tumor surveillance and its defenses against infection. There is no evidence that COPAXONE^® does this, but there has not been a systematic evaluation of this risk.

Hepatic Injury: Cases of hepatic injury, some severe, including liver failure and hepatitis with jaundice, have been reported with COPAXONE^®. Hepatic injury has occurred from days to years after initiating treatment with COPAXONE^®. If signs or symptoms of liver dysfunction occur, consider discontinuation of COPAXONE^®.

Common Adverse Reactions: In controlled studies of COPAXONE^® 20 mg per mL, the most common adverse reactions with COPAXONE^® vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%).

In a controlled study of COPAXONE^® 40 mg per mL, the most common adverse reactions with COPAXONE^® vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of COPAXONE^®. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with COPAXONE^® than placebo.

Please see full Prescribing Information for COPAXONE^®.

Injections for 3-times-a-week COPAXONE^® 40 mg must be at least 48 hours apart.

Reference:

COPAXONE^® (glatiramer acetate injection) Current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc.

COPAXONE® FOR MULTIPLE SCLEROSIS TREATMENT